Kenro Chikazawa

Dr. Kenro Chikazawa

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Gynecology and Minimally Invasive Therapy
Verified
Journal Article
Open access
PDF file
KCKenro Chikazawa
Kenro Chikazawa
SNSachiho Netsu
Sachiho Netsu
KIKen Imai
Ken Imai
AKAzusa Kimura
Azusa Kimura
TKTomoyuki Kuwata
Tomoyuki Kuwata
RKRyo Konno
Ryo Konno
Objectives: The objective of the study was to investigate the long-term outcomes, in particular, recurrence risk, especially tumor volume, for Stage IA endometrial cancer and to identify the risk factors for recurrence. Materials and Methods: This single-center retrospective study analyzed women who underwent primary surgical treatment for the International Federation of Gynecology and Obstetrics Stage IA (Grade 1 or 2) endometrioid carcinoma at our institute between January 2010 and July 2018. Patients' demographic characteristics, including age, operative time, number of lymph nodes, final stage, volume index as tumor volume, and final histological type, were reviewed. A total of 168 patients were enrolled, with 95 and 73 patients in the laparotomy and laparoscopy groups, respectively. The Cox proportional hazards model was used to adjust for prognostic factors in the analysis including upstaged patients, tumor histology, lymphovascular invasion, and volume index. Results: There was no difference in the recurrence rate between laparoscopic and open surgeries for Stage IA endometrial cancer. The operative time was longer, and the amount of blood loss was lesser in the laparoscopy group than in the laparotomy group. For all patients undergoing either laparoscopy or open surgery, upstaged ≥IB, nonendometrioid Grade 1 or 2, lymphovascular invasion, and volume index ≥36 were significant independent recurrence risk factors. Conclusion: Laparoscopic surgery for Stage IA endometrial cancer is technically and oncologically safe. Patients with a high-volume index have a higher recurrence risk. Furthermore, the volume index can be a recurrence predictor in low-risk endometrial cancer patients.

19 January 2016 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
KCKenro Chikazawa
Kenro Chikazawa
SNSachiho Netsu
Sachiho Netsu
SMShigeru Motomatsu
Shigeru Motomatsu
RKRyo Konno
Ryo Konno

29 October 2014 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
KCKenro Chikazawa
Kenro Chikazawa
JMJunji Mitsushita
Junji Mitsushita
SNSachiho Netsu
Sachiho Netsu
RKRyo Konno
Ryo Konno

24 January 2024 in Gynecologic Oncology
Verified
Journal Article
Closed access
KCKenro Chikazawa
Kenro Chikazawa
SMSatoru Muro
Satoru Muro
KYKumiko Yamaguchi
Kumiko Yamaguchi
KIKen Imai
Ken Imai
TKTomoyuki Kuwata
Tomoyuki Kuwata
KAKeiichi Akita
Keiichi Akita

20 November 2018 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
KCKenro Chikazawa
Kenro Chikazawa
KIKen Imai
Ken Imai
SLShikano Liang-Cheng
Shikano Liang-Cheng
SSShigetane Sasaki
Shigetane Sasaki
IHIsao Horiuchi
Isao Horiuchi
KTKenjiro Takagi
Kenjiro Takagi
We present a case involving conservative treatment of placenta accreta, with a subsequent diagnosis of Asherman’s syndrome. A 41-year-old Japanese woman (G2P0A2) delivered a healthy male infant via cesarean section due to preeclampsia. The placenta did not spontaneously separate and was manually removed. Adhesion was tight and placenta accreta was diagnosed. During the procedure, no uterine inversion or perforation, and no uterine cavity adhesion, were observed. Four months postoperatively, hysteroscopy was performed. Adhesion was detected at the fundus of her uterus where the placenta had adhered to the uterus. Asherman’s syndrome was diagnosed. Asherman’s syndrome might occur after conservative management of placenta accreta, which may be a direct cause of placenta accreta recurrence. When Asherman’s syndrome is diagnosed, the site of the placenta and adhesion should be monitored during subsequent pregnancies.

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
KCKenro Chikazawa
Kenro Chikazawa
KIKen Imai
Ken Imai
TKTomoyuki Kuwata
Tomoyuki Kuwata
RKRyo Konno
Ryo Konno
Chikazawa K, et al. J Gynecol Oncol. 2023 Dec;35:e28. https://doi.org/10.3802/jgo.2024.35.e28